Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05798611 · ClinicalTrials.gov registry record · Phase 2
Study of ART0380 in Patients With Biologically Selected Solid Tumors
A Phase 2 study, sponsored by Artios Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT05798611 is a Phase 2 study that was terminated before completion, run by Artios Pharma. The registered enrollment target is 36 participants.
The verdict
NCT05798611, a Phase 2 study, was terminated before completion, sponsored by Artios Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).
Interventions
- DRUG ART0380
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-09-06 |
| Est. Completion | 2025-05-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05798611
The ClinicalTrials.gov registry entry for NCT05798611 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Artios Pharma, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ART0380 is the first listed.
NCT05798611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05798611 about?
NCT05798611 is a clinical study titled "Study of ART0380 in Patients With Biologically Selected Solid Tumors". This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).
What is the current status of trial NCT05798611?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2023-09-06. Estimated completion is 2025-05-27.
What interventions are being tested in trial NCT05798611?
The interventions under investigation include: ART0380 (DRUG).
Who is sponsoring clinical trial NCT05798611?
This trial is sponsored by Artios Pharma, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.